Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded WarrantsGlobeNewsWire • 05/20/24
Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate UpdateGlobeNewsWire • 05/06/24
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial OfficerGlobeNewsWire • 04/16/24
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology ProgramsGlobeNewsWire • 04/09/24
Foghorn Therapeutics to Participate in Needham's 23rd Annual Virtual Healthcare ConferenceGlobeNewsWire • 04/05/24
Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 105.75% as Wall Street Analysts Expect?Zacks Investment Research • 04/02/24
Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual MeetingGlobeNewsWire • 03/26/24
Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 03/13/24
Wall Street Analysts Predict a 124.31% Upside in Foghorn Therapeutics Inc. (FHTX): Here's What You Should KnowZacks Investment Research • 03/13/24
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 03/07/24
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic OutlookGlobeNewsWire • 03/07/24
Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909GlobeNewsWire • 03/05/24
Foghorn Therapeutics to Participate in Cowen's 44th Annual Health Care ConferenceGlobeNewsWire • 02/28/24
Foghorn Therapeutics Inc. (FHTX) Moves 22.7% Higher: Will This Strength Last?Zacks Investment Research • 02/12/24
How Much Upside is Left in Foghorn Therapeutics Inc. (FHTX)? Wall Street Analysts Think 160.57%Zacks Investment Research • 12/11/23
Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual MeetingGlobeNewsWire • 12/01/23
Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate UpdateGlobeNewsWire • 11/02/23
Foghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma to Be Presented at ESMO CongressGlobeNewsWire • 10/13/23
Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International ConferenceGlobeNewsWire • 10/04/23
Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development OfficerPRNewsWire • 09/11/23
Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and/or Refractory AMLGlobeNewsWire • 08/31/23
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/04/23